How many drugs treat Bronchospasm?

Drug Landscape tracks 7 marketed treatments for Bronchospasm (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bronchospasm.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bronchospasm — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchospasm (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bronchospasm, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xopenex	LEVOSALBUTAMOL	Oak Pharms Inc	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	1999-01-01
ProAir	albuterol	Generic (originally Allen & Hanburys/GSK)	SABA (Short-acting beta-2 agonist)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor	1982-05-05
Proventil	salbutamol	Merck & Co.	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	1981-01-01
xopenex	xopenex	Phoenix Children's Hospital		Beta-2 adrenergic receptor
Theophyllin	Theophyllin	University of Bergen		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1
Levalbuterol	Levalbuterol	University of Aleppo		beta 2 -adrenergic receptors
Aminophyllin	Aminophyllin	University of Padova		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Bronchospasm
Generic (originally Allen & Hanburys/GSK) · 1 drug in Bronchospasm
Merck & Co. · 1 drug in Bronchospasm
Oak Pharms Inc · 1 drug in Bronchospasm
Phoenix Children's Hospital · 1 drug in Bronchospasm
University of Aleppo · 1 drug in Bronchospasm
University of Bergen · 1 drug in Bronchospasm
University of Padova · 1 drug in Bronchospasm

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bronchospasm:

Cite this brief

Drug Landscape (2026). Bronchospasm — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bronchospasm. Accessed 2026-06-10.

Bronchospasm full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing